Taken all the data together, we found that acquired gemcitabine resistant pancreatic cancer cells have elevated expression of GLI transcription factors, either GLI1 or GLI2, which is associated with elevated SOX2 expression. This evidence concerns the gene SOX2 and pancreatic neoplasm.